We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Establishing Comparable Requirements and Treatment Groups Before Applying Statistical Comparison

Claudia Stöllberger, MD1; Josef Finsterer, MD, PhD1
[+] Author Affiliations
1Krankenanstalt Rudolfstiftung, Wien, Österreich
JAMA Neurol. 2014;71(3):369-370. doi:10.1001/jamaneurol.2013.5966.
Text Size: A A A
Published online


To the Editor With interest we read the article by Chatterjee et al,1 who performed a meta-analysis to quantitatively assess the rates of intracranial hemorrhage (ICH) occurring in randomized trials investigating the new oral anticoagulants (NOACs) dabigatran, rivaroxaban, and apixaban in patients with atrial fibrillation. They found that each of the 3 drugs reduced the risk for ICH and concluded that any of the currently available NOACs can be considered first line for patients at high risk for ICH.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





March 1, 2014
Manolis S. Kallistratos, MD, PhD, FESC; Leonidas E. Poulimenos, MD, FESC; Athanasios J. Manolis, MD, FESC
1Department of Cardiology, Asklepeion General Hospital, Athens, Greece
JAMA Neurol. 2014;71(3):370-371. doi:10.1001/jamaneurol.2013.5963.
March 1, 2014
Saurav Chatterjee, MD; Partha Sardar, MD; Giuseppe Biondi-Zoccai, MD; Dharam J. Kumbhani, MD, SM, MRCP
1Division of Cardiology, St Lukes-Roosevelt Hospital, Mount Sinai Health System, New York, New York
2Department of Medicine, New York Medical College–Metropolitan Hospital Center, New York, New York
3Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy
4Division of Cardiology, University of Texas Southwestern, Dallas, Texas
JAMA Neurol. 2014;71(3):371-372. doi:10.1001/jamaneurol.2013.6003.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...